§ — Researched for · Sleep & recovery
No peptide has a proven, approved use for sleep. The candidates discussed — emideltide (DSIP), epitalon, and GH secretagogues — rest on decades-old inconsistent studies or on animal data. In July 2026 an FDA advisory committee voted against listing emideltide and narrowly backed epitalon; FDA has not decided.
Reviewed October 2026 · Sources: FDA, EMA
02 — What is being studied
Two mechanisms are under study. One is direct sleep signalling: delta-sleep-inducing peptide was isolated from rabbit cerebral venous blood in the 1970s and tested in small human studies with inconsistent results on sleep latency and slow-wave sleep. The other is indirect, through the growth hormone axis, since GH secretion is coupled to slow-wave sleep and secretagogues shift that pattern.
The endpoints that would settle the question — polysomnography-confirmed sleep architecture, sleep efficiency, next-day function, all against placebo — have not been measured in modern controlled trials for any peptide in this group. Epitalon rests on Russian-language work with pineal regulation as its stated mechanism and no published clinical sleep data. Animal and mechanistic plausibility is not an outcome, and as of October 2026 this group has plausibility without outcomes.
03 — The table
| Peptide | Researched for | Evidence | Regulatory status | As of |
|---|---|---|---|---|
| CJC-1295 | Sustained growth hormone and IGF-1 elevation in adults; body composition. | B | Not FDA-approved. Its nomination was withdrawn and it left 503A Category 2 in September 2024. The advisory committee reviewed it on December 4, 2024, and did not recommend it for the 503A Bulks List. It cannot be compounded under section 503A. | 2026-10-22 |
| Ipamorelin | Postoperative ileus (a completed phase 2 program); growth hormone release. | B | Not FDA-approved. Its nomination was withdrawn and it left 503A Category 2 in September 2024. The advisory committee reviewed it on October 29, 2024, and did not recommend it for the 503A Bulks List. It cannot be compounded under section 503A. | 2026-10-22 |
| Emideltide | Sleep induction, stress response, chronic pain, opioid withdrawal. | C | Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. On July 24, 2026, the advisory committee voted 6–7 (one abstention) against recommending it for the 503A Bulks List. It cannot be compounded under section 503A. | 2026-10-22 |
| Epitalon | Telomerase activation, melatonin regulation, lifespan extension. | D | Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. On July 24, 2026, the advisory committee voted 7–4 (one abstention) to recommend it for the 503A Bulks List, against the advice of FDA's scientists. FDA has not decided; it cannot yet be compounded under section 503A. | 2026-10-22 |
04 — Per peptide
Regulatory status · United States · as of October 2026
Not FDA-approved. Its nomination was withdrawn and it left 503A Category 2 in September 2024. The advisory committee reviewed it on December 4, 2024, and did not recommend it for the 503A Bulks List. It cannot be compounded under section 503A.
Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026
Researched forSustained growth hormone and IGF-1 elevation in adults; body composition.
Full profile: CJC-1295 →Regulatory status · United States · as of October 2026
Not FDA-approved. Its nomination was withdrawn and it left 503A Category 2 in September 2024. The advisory committee reviewed it on October 29, 2024, and did not recommend it for the 503A Bulks List. It cannot be compounded under section 503A.
Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026
Researched forPostoperative ileus (a completed phase 2 program); growth hormone release.
Full profile: Ipamorelin →Regulatory status · United States · as of October 2026
Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. On July 24, 2026, the advisory committee voted 6–7 (one abstention) against recommending it for the 503A Bulks List. It cannot be compounded under section 503A.
Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026
Researched forSleep induction, stress response, chronic pain, opioid withdrawal.
Full profile: Emideltide →Regulatory status · United States · as of October 2026
Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. On July 24, 2026, the advisory committee voted 7–4 (one abstention) to recommend it for the 503A Bulks List, against the advice of FDA's scientists. FDA has not decided; it cannot yet be compounded under section 503A.
Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026
Researched forTelomerase activation, melatonin regulation, lifespan extension.
Full profile: Epitalon →05 — What the data does not show
Reliable improvement in sleep quality or recovery has not been shown for any peptide in this group.
06 — Questions for your physician
Every practice in the registry that lists peptide therapy, sorted by distance and nothing else. You contact the practice directly.
La Jolla, CA
Focus matches this goal: Biological Age & Epigenetics, Cognition & Brain Health, Functional Medicine
No physician listed on the practice website
Alpharetta, GA
Focus matches this goal: Advanced Blood Biomarkers, Cancer Screening & Early Detection, Cognition & Brain Health
Physician credentials on file
San Francisco, CA
Focus matches this goal: Advanced Blood Biomarkers, Biological Age & Epigenetics, Cognition & Brain Health
Ahvie Herskowitz, MD · Ann Lee, MD
Steamboat Springs, CO
Focus matches this goal: Cognition & Brain Health, Concierge / Membership Model, DEXA / Body Composition
Physician credentials on file
Austin, TX
Focus matches this goal: Advanced Blood Biomarkers, Cancer Screening & Early Detection, Cognition & Brain Health
Physician credentials on file
North Palm Beach, FL
Focus matches this goal: Biological Age & Epigenetics, Cognition & Brain Health, Concierge / Membership Model
No physician listed on the practice website
Listed for transparency, not as an endorsement of any practice, substance or protocol. Most peptides are not FDA-approved for the uses they are offered for.
Reviewed October 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.
Most peptides used in longevity practice are not FDA-approved for these uses. Check the status of each substance first.